張莉,研究員,博士生導師。本科畢業(yè)于中山大學公共衛(wèi)生學院預防醫(yī)學專業(yè),博士畢業(yè)于北京協(xié)和醫(yī)學院流行病與衛(wèi)生統(tǒng)計專業(yè)。曾獲WHO/IARC博士后獎學金、2020年國際乳頭瘤病毒大會會議獎學金、2018年亞洲及太平洋癌癥預防組織大會最佳口頭報告獎、2018年中國腫瘤學大會中青年優(yōu)秀論文三等獎、2017國際乳頭瘤病毒大會會議獎學金。
     院校引進人才,2023年加入院校。曾于2019年11月-2022年12月在世界衛(wèi)生組織/國際癌癥研究署(WHO/IARC)從事博士后研究員工作。
依托國內(nèi)以人群為基礎的腫瘤篩查長期隨訪隊列和國際腫瘤篩查實施評估平臺,在常見惡性腫瘤的篩查方案優(yōu)化、組織實施評估、國際專家共識等領域開展了一系列研究,研究成果被國際權威手冊/指南引用,并多次獲得國際會議的會議獎學金資助。以第一作者身份在 Nature Medicine,EClinicalMedicine,BMC Medicine 等雜志發(fā)表論文十余篇,主持醫(yī)科院創(chuàng)新工程、世界衛(wèi)生組織/國際癌癥研究署(WHO/IARC)博士后歸國基金、國家自然科學基金、科技部海外博士后引才項目等研究。
1. Zhong P, Zhang L*, Zhao F*. Modeling cervical cancer elimination: a pathway to inform policy decisions. Cancer Biol Med. 2025 Oct 6;22(9):1002–9.
2. Han J#, Zhang L#, Chen Y#, Zhang Y, Wang L, Cai R, Li M, Dai Y, Dang L, Chen H*, Zhu L*. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine. 2025 Jun 9;84:103290.
3. Li Zhang#, Isabel Mosquera, Eric Lucas, Mary Luz Rol, Andre L. Carvalho, Partha Basu*, CanScreen5 collaborators. Organisation and implementation of breast, cervical and colorectal cancer screening programmes from 84 countries: the CanScreen5 global repository, Nature Medicine, 2023;29(5):1135-1145.
4. Li Zhang#, Catherine Sauvaget, Isabel Mosquera, Partha Basu*. Efficacy, acceptability and safety of ablative vs excisional procedure in the treatment of histologically confirmed CIN2-3: a systematic review. BJOG. 2023;130(2):153-61.
5. Li Zhang#, André L Carvalho, Isabel Mosquera, Tianmeng Wen, Eric Lucas, Catherine Sauvaget, Richard Muwonge, Marc Arbyn, Elisabete Weiderpass, Partha Basu*. An international consensus on the essential and desirable criteria for an ‘organized’ cancer screening programme. BMC Med. 2022,23;20(1):101. (R)
6. Li Zhang#, Xuelian Zhao, Shangying Hu, Shimin Chen, Shuang Zhao, Li Dong, André L Carvalho, Richard Muwonge, Fanghui Zhao*, Partha Basu. Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study. Int J Cancer.2022;151(6):878-87.
7. Mengmeng Li#*, Li Zhang#, Hadrien Charvat*, Matthew E. Callister, Peter Sasieni, Evangelia Christodoulou, Rudolf Kaaks, Mattias Johansson, Andre L. Carvalho, Salvatore Vaccarella, Hilary A. Robbins*. The influence of post-screening follow-up time and other factors on estimates of overdiagnosis from lung cancer screening trials. Int J Cancer. 2022;151(9):1491-501.